Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis
- PMID: 28247169
- DOI: 10.1007/s11255-017-1554-6
Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis
Abstract
Objective: To investigate the role of neutrophil-to-lymphocyte ratio as a prognostic indicator in patients with localized clear cell renal cell carcinoma treated with radiofrequency ablation.
Patients and methods: We retrospectively analyzed data from patients with renal cell carcinoma who underwent radiofrequency ablation from 2006 to 2013. The Kaplan-Meier method was used to generate the survival curves according to different categories of neutrophil-to-lymphocyte ratio. Relationships between preoperative neutrophil-to-lymphocyte ratio or the change of neutrophil-to-lymphocyte ratio and survival were evaluated with multivariable Cox proportional hazards regression analysis. A propensity score matching analysis was carried out to avoid confounding bias.
Results: A total of 185 patients were included in present study. When stratified by preoperative neutrophil-to-lymphocyte ratio cutoff value of 2.79, 5-year recurrence-free survival, 5-year disease-free survival, and 5-year overall survival rates of neutrophil-to-lymphocyte ratio <2.79 versus ≥2.79 were 100, 98.5, and 99.2% versus 80.5, 72.6, and 90.6%, respectively (P < 0.001, P < 0.001, P = 0.003). In terms of propensity score matching analysis, 5-year recurrence-free survival, 5-year disease-free survival, and 5-year overall survival rates of neutrophil-to-lymphocyte ratio <2.79 versus ≥2.79 were 100, 97.9, and 100% versus 82.3, 73.4, and 89.4%, respectively (P = 0.003, P = 0.001, P = 0.022). When combining preoperative neutrophil-to-lymphocyte ratio with the change of neutrophil-to-lymphocyte ratio, patients with both preoperative neutrophil-to-lymphocyte ratio ≥2.79 and the change of neutrophil-to-lymphocyte ratio ≥0.40 had the worst disease-free survival. Results of multivariable analysis showed that preoperative neutrophil-to-lymphocyte ratio and the change of neutrophil-to-lymphocyte ratio correlated with cancer relapse remarkably.
Conclusions: High preoperative neutrophil-to-lymphocyte ratio and elevated postoperative neutrophil-to-lymphocyte ratio are associated with significant increase in risk of local recurrence as well as distant metastasis. The combination of neutrophil-to-lymphocyte ratio with the other prognostic indicators can be applied in the evaluation of relapse risk in patients with clear cell renal cell carcinoma after radiofrequency ablation.
Keywords: Ablation techniques; Kidney neoplasms; Neutrophil-to-lymphocyte ratio; Survival.
Similar articles
-
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.J Urol. 2013 Dec;190(6):1999-2004. doi: 10.1016/j.juro.2013.06.082. Epub 2013 Jul 2. J Urol. 2013. PMID: 23831313
-
Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.Urol Oncol. 2016 May;34(5):239.e9-15. doi: 10.1016/j.urolonc.2015.12.006. Epub 2016 Jan 21. Urol Oncol. 2016. PMID: 26803433
-
Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma.J Urol. 2012 Feb;187(2):411-7. doi: 10.1016/j.juro.2011.10.026. Epub 2011 Dec 15. J Urol. 2012. PMID: 22177153
-
Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis.BMJ Open. 2015 Apr 8;5(4):e006404. doi: 10.1136/bmjopen-2014-006404. BMJ Open. 2015. PMID: 25854964 Free PMC article. Review.
-
Meta analysis of clinical prognosis of radiofrequency ablation versus partial nephrectomy in the treatment of early renal cell carcinoma.Front Oncol. 2023 Apr 25;13:1105877. doi: 10.3389/fonc.2023.1105877. eCollection 2023. Front Oncol. 2023. Retraction in: Front Oncol. 2024 Feb 20;14:1383353. doi: 10.3389/fonc.2024.1383353. PMID: 37182152 Free PMC article. Retracted.
Cited by
-
Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.Radiology. 2019 Jul;292(1):25-34. doi: 10.1148/radiol.2019182326. Epub 2019 Apr 23. Radiology. 2019. PMID: 31012818 Free PMC article. Review.
-
Pre-operative serum inflammation-based scores in patients with pituitary adenomas.Pituitary. 2021 Jun;24(3):334-350. doi: 10.1007/s11102-020-01112-5. Epub 2020 Nov 24. Pituitary. 2021. PMID: 33230695
-
Serum Inflammation-based Scores in Endocrine Tumors.J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3796-e3819. doi: 10.1210/clinem/dgab238. J Clin Endocrinol Metab. 2021. PMID: 33837783 Free PMC article. Review.
-
Systemic inflammatory markers and serum lactate dehydrogenase predict survival in patients with Wilms tumour.Arch Med Sci. 2021 Apr 18;18(5):1253-1261. doi: 10.5114/aoms/125543. eCollection 2022. Arch Med Sci. 2021. PMID: 36160344 Free PMC article.
-
Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.Semin Intervent Radiol. 2019 Oct;36(4):334-342. doi: 10.1055/s-0039-1696704. Epub 2019 Oct 31. Semin Intervent Radiol. 2019. PMID: 31680725 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical